Elad Sharon: Quite promising for c-MET over-expressing NSCLC

Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, adding:

“Wow! This looks quite promising for c-MET over-expressing NSCLC! Let the march of ADCs continue in oncology!”

Quoting Giuseppe Banna’s post:

“The Phase II LUMINOSITY trial shows promising results for Telisotuzumab Vedotin in treating c-Met protein–overexpressing advanced NSCLC, especially in patients with high c-Met expression.”

“Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.”

Authors: Ross Camidge, Jair Bar, Hidehito Horinouchi, Christine Ratajczak, Shun Lu et al.

Sources: Elad Sharon/X and Giuseppe Banna/X